NEWS

NEWS

Total 83

73
NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
2022-11-04
72
NeoImmuneTech Joins the United Nations Global Compact
2022-10-11
71
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
2022-10-06
70
QUARTERLY UPDATE (Q3 2022)
2022-10-04
69
NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
2022-09-13
68
NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
2022-08-08
67
NeoImmuneTech to Present at Cytokine-Based Drug Development Summit
2022-07-26
66
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme
2022-07-13
65
QUARTERLY UPDATE (2Q 2022)
2022-07-12
64
Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing
2022-07-04

1 2 3 4 5 >>>